Karyopharm Therapeutics Inc. 8K

Karyopharm Therapeutics Inc. agreed, as part of a forbearance arrangement with its lenders, to pay $20 million of fees in the form of new convertible preferred stock and to amend certain existing warrants held by those lenders.

Karyopharm Therapeutics Inc. entered into a fee agreement, effective September 10, 2026, in connection with a contemporaneous Forbearance Agreement with its lenders, under which the company will satisfy a $20 million aggregate fee obligation by issuing 20,000 shares of a new Series A 0% convertible perpetual preferred stock (with a $1,000 per share liquidation preference and a $1.62 conversion price into common stock) to the participating lenders, while also amending certain existing common stock purchase warrants held by those lenders to strengthen successor entity obligations in the event of future fundamental transactions, and providing for potential registration rights and customary legal and tax covenants.

Filing Facts

CIK

1503802

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-388621

Alert Tier

7